Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris

The New England Journal of Medicine
U ThadaniS H Taylor


We compared the immediate effects of five beta-adrenoreceptor-blocking agents in 16 patients with stable angina pectoris. Acute dose-response studies showed that all five drugs improved exercise tolerance and reduced ST-segment depression, heart rate and blood pressure by a similar degree in comparison with a placebo (P less than 0.01). Near maximum improvement in exercise tolerance occurred when the acute cumulative oral dose had reached 160 mg for propranolol and oxprenolol, 200 mg for metoprolol and tolamolol and 400 mg for practolol. When these drugs were administered as a single doses, increase in walking time before the development of angina and reduction in ST-segment depression, heart rate and systolic blood pressure all occurred within one hour and persisted for eight hours--effects markedly different from the response to a placebo (P less than 0.01). These data show that non-cardioselective agents (propranolol and oxprenolol), cardioselective agents (practolol, metoprolol and tolamolol), as well as drugs with intrinsic sympathomimetic activity (oxprenolol and practolol), were equally effective in the treatment of angina pectoris.


Oct 1, 1980·The American Journal of Cardiology·T Ishizaki
Apr 1, 1983·British Journal of Plastic Surgery·D W Robins
Apr 1, 1984·Journal of the American College of Cardiology·M TolinsG L Pierpont
Aug 27, 1981·The New England Journal of Medicine·J Koch-Weser, W H Frishman
Apr 21, 1983·The New England Journal of Medicine·W H Frishman
Jan 5, 1984·The New England Journal of Medicine·T A LouisM Polansky
Dec 5, 1985·The New England Journal of Medicine·K Godfrey
Apr 1, 1984·British Heart Journal·J HerlitzL Wilhelmsen
Oct 5, 1984·The American Journal of Medicine·D T LowenthalK Conry
Jul 1, 1980·The American Journal of Cardiology·U Thadani, J O Parker
Oct 1, 1984·American Heart Journal·A J Wood
Apr 1, 1984·British Journal of Clinical Pharmacology·C G Regårdh, G Johnsson
Sep 24, 2016·Expert Opinion on Drug Safety·Talla A RousanU Thadani
Jan 26, 2017·Drugs·Talla A RousanU Thadani
May 1, 1987·International Journal of Cardiology·R J Northcote
Sep 21, 2004·Journal of Cardiovascular Pharmacology and Therapeutics·U Thadani
Sep 8, 2017·Nature Reviews. Cardiology·Roberto FerrariJosé L Lopez-Sendon
Sep 1, 1991·DICP : the Annals of Pharmacotherapy·T T Sproat, L M Lopez
Jan 1, 1985·Acta Medica Scandinavica. Supplementum·U Thadani
Jul 1, 1984·Drug Intelligence & Clinical Pharmacy·C D Black, H J Mann
Nov 1, 1983·British Journal of Clinical Pharmacology·B SilkeS H Taylor


Jul 3, 1976·British Medical Journal·C DavidsonS H Taylor
Feb 1, 1975·Thorax·E SowtonI Baker
Dec 4, 1971·Lancet·H J Waal-Manning, F O Simpson
Jan 20, 1973·British Medical Journal·U ThadaniS H Taylor
Aug 27, 1966·British Medical Journal·D A Birkett, D A Chamberlain
Dec 1, 1967·Annals of Internal Medicine·R E GianellyD C Harrison
Sep 1, 1966·The American Journal of Cardiology·S WolfsonR Gorlin
Apr 6, 1968·British Medical Journal·R Ormrod

Related Concepts

Systolic Blood Pressure Measurement
Diastolic Blood Pressure
Cardiopulmonary Exercise Test
Angina Pectoris

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.